Without insulin ... a new strategy for treating diabetes

In a recent scientific study, a promising therapeutic strategy was revealed to deal with type 2 diabetes, which would significantly reduce, or eliminate the need for patient insulin therapy. The study was revised during the activities of the United European Digestive Disease Assembly, held in Austria, and the innovative strategy depends on the combination of a new technology known as ‘electropification’, with semaglutide, which led to eliminating the need for insulin at 86% of patients participating in the study. Electropification is a process in which short electrical impulses are used to temporarily open the pores of cells, allowing certain tissues to be rebuilt in the pancreas; The organ responsible for insulin production in the body, which is the hormone needed to regulate the level of sugar in the blood. As for the ‘semaglutide’, it is a drug already used to treat type 2 diabetes and reduce weight in obese people as it stimulates insulin secretion and reduces the appetite, which helps control blood sugar levels. When combining ‘semaglutide’ with electropology, the research has shown that this approach can improve the pancreatic functions and reduce the dependence on the body of the external insulin. The clinical trials of this therapeutic strategy showed many encouraging results; 86% of patients who received this treatment were fully apart from insulin, representing tremendous progress in dealing with diabetes; This means that patients can rely more on their own ability to produce insulin, without continuous injection. Type 2 Type 2 diabetes affects the second type of 222 million people around the world, while obesity is considered a major risk factor. Although insulin therapy is frequently used to manage blood sugar levels in type 2 diabetics, it can lead to side effects such as weight gain and increased complexity of diabetes handling, which confirm the need for alternative treatment strategies. The first study on people included 14 participants, between the ages of 28 and 75, with body mass indicators of 24 to 40 kg per square meter. Each participant underwent a procedure for electropology under deep anesthesia, and after the procedure, the participants dedicated to an equal caloric liquid diet for two weeks, after which the dose of the semag loides gradually increased to 1 mg each week. After a period of between 6 and 12 months, 86% of participants (12 out of 14) no longer have to treat insulin, and this success continued during the 24 -month follow -up, as all patients in these cases maintained control of blood sugar, with the accumulated sugar levels less than 7.5%. 93% of patients carry the maximum dose of semagoid, and no single individual was able to reach the maximum dose; Due to nausea, no serious side effects have been reported. The benefits of reducing insulin and reducing insulin dependence holds multiple health benefits; Patients who rely on insulin for a long time may have complications such as weight gain, or fluctuations in blood sugar levels, or problems in the skin and blood vessels due to regular injection, and insulin means to significantly reduce these risks and improve the general balance of the body. In addition to the health benefits, this treatment is also an economic innovative solution, as the cost of insulin therapy is a major burden on both health systems and patients, and reducing the need for insulin can reduce this long -term cost. The researchers believe that the new method, which reverses the drug therapy that needs daily dedication to medication, addresses the critical issue of the patient’s continuous commitment to the management of type 2 diabetes. In addition, treatment adjusts the disease by improving the patient’s inner sensitivity to insulin, and treating the radical cause of the disease, as opposed to the currently available drug treatments, which controls the handling of the disease at the best case.